- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04640649
Prediction of Progression of Age-Related Macular Degeneration
A Novel Approach to Personalized Prediction of Progression of Age-Related Macular Degeneration
The goal for this study is to initiate a randomized, controlled clinical trial to test the viability of personalized AMD progression prediction models. Early and intermediate AMD patients will be recruited and randomly assigned them to a control or test group. The test group will include patients who will receive personalized follow-up care based on their predicted risk, and collect baseline and follow-up data.
This work will advance the AMD field by improving the identification of high-risk patients as candidates for more frequent screening and earlier treatment, leading to better clinical outcomes.
Study Overview
Status
Intervention / Treatment
Detailed Description
More than 90% of patients with advanced AMD have severe vision loss. Predicting AMD progression from an early or intermediate stage is crucial, since prompt intervention after a choroidal neovascularization (CNV) event and geographic atrophy (GA) monitoring can greatly improve visual outcomes. Patients at higher risk of progression should have more frequent follow-up visits, since progression often occurs before any visual changes are noticed by the patient. Previous work has determined the risk factors for AMD progression based on drusen features in fundus photos, Optical Coherence Tomography (OCT) and from genetic factors. However, current models are limited by their ability to make predictions over short intervals, which limits their utility in guiding screening intervals.
In this study we will recruit patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion. We will perform a randomized trial where we will randomly assign them to a control or test group (personalized follow-up care starting at 3 months based on their predicted risk from algorithm results), and collect baseline genetic, demographic, imaging, and clinical data and first follow-up data at the 3 month and 6 month follow-up time points. Outcomes will be measured to determine if an algorithm predicting early follow-up for high-risk patients (3 month) is advantageous over the standard 6 month follow-up time point.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joelle A Hallak, PhD
- Phone Number: 3129960157
- Email: joelle@uic.edu
Study Contact Backup
- Name: Kathleen Romond, MPH
- Email: kromon2@uic.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-neovascular AMD at baseline in at least one eye with no signs of GA,
- > 45 years of age,
- willingness to participate through a signed consent form.
Exclusion Criteria:
- Pregnant women and vulnerable populations
- Participation in an investigational trial that involves treatment with any drug (with the exception of vitamins or minerals) within 3 months prior to Day 1.
- Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prediction Algorithm
Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
|
Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group.
The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD.
If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
|
No Intervention: Control
Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Acuity
Time Frame: one year
|
The primary outcome measure will be the difference in visual acuity between test and control patients in those who progressed to late stage AMD
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Actual risk of conversion
Time Frame: one year
|
The actual risk/ of conversion to wet AMD will be calculated for each eye that progressed using regression analysis.
This risk will be compared to the risk that the algorithm predicted.
|
one year
|
Number of visits
Time Frame: one year
|
Number of visits will be compared between the test arm and the control arm of patients who progression to wet AMD
|
one year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joelle A Hallak, PhD, University of Illinois at Chicago
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-0460
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
University of Modena and Reggio EmiliaCompletedMacular Degeneration Advanced | Macular Degeneration, Dry | Macular Degeneration, Senile | Macular Scar | Macular Degeneration NonexudativeItaly
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Clinical Trials on Algorithm prediction
-
Sun Yat-sen UniversityUnknownRefractive ErrorsChina
-
Sun Yat-sen UniversityUnknown
-
National University Hospital, SingaporeCompleted
-
National Taiwan University HospitalNot yet recruitingthe Intraoperative Hypotension
-
University of ArizonaUnknown
-
Assiut UniversityNot yet recruiting
-
West China HospitalRecruiting
-
National University of SingaporeCompletedHealth Knowledge, Attitudes, PracticeSingapore